MX2022006873A - Formulaciones de capsulas y tabletas de liberacion inmediata estables de 1-((2s,5r)-5-((7h-pirrolo[2,3-d]pirimidin-4-il)amino)- 2-metilpiperidin-1-il)prop-2-en-1-ona. - Google Patents

Formulaciones de capsulas y tabletas de liberacion inmediata estables de 1-((2s,5r)-5-((7h-pirrolo[2,3-d]pirimidin-4-il)amino)- 2-metilpiperidin-1-il)prop-2-en-1-ona.

Info

Publication number
MX2022006873A
MX2022006873A MX2022006873A MX2022006873A MX2022006873A MX 2022006873 A MX2022006873 A MX 2022006873A MX 2022006873 A MX2022006873 A MX 2022006873A MX 2022006873 A MX2022006873 A MX 2022006873A MX 2022006873 A MX2022006873 A MX 2022006873A
Authority
MX
Mexico
Prior art keywords
pyrrolo
pyrimidin
prop
amino
immediate release
Prior art date
Application number
MX2022006873A
Other languages
English (en)
Inventor
Ian Leonard Smales
Andrew Richard Barrett
Rand Dhiyaa Turki
Suet Mei Wong
Original Assignee
Pfizer R&D Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer R&D Uk Ltd filed Critical Pfizer R&D Uk Ltd
Publication of MX2022006873A publication Critical patent/MX2022006873A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se dirige a nuevas formulaciones de tabletas y cápsulas de liberación inmediata estables para el inhibidor Janus Cinasa 3 (JAK3) de para-toluensulfonato de 1-((2S,5R)-5-((7H-pirrolo[2,3-d]pirimidin-4-il)amino)-2-metilpipe ridin-1-il)prop-2-en-1-ona que tiene la estructura. (ver Fórmula).
MX2022006873A 2019-12-31 2020-12-29 Formulaciones de capsulas y tabletas de liberacion inmediata estables de 1-((2s,5r)-5-((7h-pirrolo[2,3-d]pirimidin-4-il)amino)- 2-metilpiperidin-1-il)prop-2-en-1-ona. MX2022006873A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962955497P 2019-12-31 2019-12-31
PCT/IB2020/062524 WO2021137160A1 (en) 2019-12-31 2020-12-29 Stable immediate release tablet and capsule formulations of 1-((2s,5r)-5-((7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one

Publications (1)

Publication Number Publication Date
MX2022006873A true MX2022006873A (es) 2022-08-18

Family

ID=74125579

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006873A MX2022006873A (es) 2019-12-31 2020-12-29 Formulaciones de capsulas y tabletas de liberacion inmediata estables de 1-((2s,5r)-5-((7h-pirrolo[2,3-d]pirimidin-4-il)amino)- 2-metilpiperidin-1-il)prop-2-en-1-ona.

Country Status (9)

Country Link
US (1) US20230338380A1 (es)
EP (1) EP4084780A1 (es)
KR (1) KR20220123271A (es)
AU (1) AU2020417043A1 (es)
BR (1) BR112022010101A2 (es)
CA (1) CA3166050C (es)
IL (1) IL292929A (es)
MX (1) MX2022006873A (es)
WO (1) WO2021137160A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY187446A (en) 2013-12-05 2021-09-22 Pfizer Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
JP6748619B2 (ja) 2017-09-20 2020-09-02 日立オートモティブシステムズ株式会社 車両制御装置、車両制御方法および車両制御システム
JP6944496B2 (ja) * 2018-10-22 2021-10-06 ファイザー・インク ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体

Also Published As

Publication number Publication date
BR112022010101A2 (pt) 2022-09-06
IL292929A (en) 2022-07-01
AU2020417043A1 (en) 2022-06-09
EP4084780A1 (en) 2022-11-09
CA3166050A1 (en) 2021-07-08
US20230338380A1 (en) 2023-10-26
KR20220123271A (ko) 2022-09-06
CN115023221A (zh) 2022-09-06
WO2021137160A1 (en) 2021-07-08
CA3166050C (en) 2024-02-20

Similar Documents

Publication Publication Date Title
MY145332A (en) Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
MY139336A (en) N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY149044A (en) Pyrazolopyrimidines - derivatives as cyclin dependent kinase inhibitors
MX2021003241A (es) Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricacion e intermediario al mismo.
MXPA03010207A (es) Nuevas 4-anilinoquinolin-3-carboxamidas.
MX2009003734A (es) Pirazolopirimidinas como inhibidor de cinasas dependientes de ciclina.
MXPA05011296A (es) Conjugados de fosfonato inhibidores de la cinasa.
SG10201906517VA (en) Synthesis of a bruton's tyrosine kinase inhibitor
NZ629807A (en) Novel pyrrolopyrimidine compounds as inhibitors of protein kinases
NO20051647L (no) Pyrazolopyrimidiner som syklinavhengige kinaseinhibitorer
ECSP066763A (es) Pirazolopirimidinas novedosas como inhibidores de quinasa ciclina-dependientes
MX2009011355A (es) Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas.
MY162134A (en) Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
CL2008003023A1 (es) (s)-4-amino-n-(1-(4-clorofenil)-3-hidroxipropil)-1-(7h-pirrolo[2,3-d]pirimidin-4-il)piperidina-4-carboxamida, inhibidor de la proteina quinasa b; procedimiento de preparacion; compuestos intermediarios; composicion farmacéutica que comprende dicho compuesto; y uso para el tratamiento del cancer.
MD4735C1 (ro) Derivaţi ai pirolo[2,3-d]pirimidinei ca inhibitori de Kinaze Janus-asociate (JAK)
MXPA05005199A (es) Compuestos de pirimidina.
WO2010011375A3 (en) Inhibitors of janus kinases
MX2009003733A (es) Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina.
WO2007061764A3 (en) Tricyclic compounds useful as inhibitors of kinases
HK1112233A1 (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors for the treatment of cancer
TW200420564A (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY143466A (en) Inhibitors of tyrosine kinases
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
MY134589A (en) Imidazopyrazines as cyclin dependent kinase inhibitors